{"id":45476,"date":"2022-06-24T14:01:58","date_gmt":"2022-06-24T12:01:58","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\/"},"modified":"2022-06-24T14:01:58","modified_gmt":"2022-06-24T12:01:58","slug":"investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\/","title":{"rendered":"Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV"},"content":{"rendered":"
\n

\n\u2013 Recommendation is Based on Week 26 Data from the CAPELLA Trial Showing Twice-Yearly Lenacapavir Achieved High Rates of Virologic Suppression in Heavily Treatment-Experienced People with HIV \u2013<\/i><\/b>\n<\/p>\n

\n\u2013 If Authorized, Lenacapavir Could Offer a New, Every Six-Month Treatment Option for People with Limited Treatment Choices <\/i>\u2013<\/i><\/b>\n<\/p>\n

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for investigational lenacapavir for the treatment of HIV-1 infection, in combination with other antiretroviral(s), in adults with multi-drug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.\n<\/p>\n

<\/a><\/p>\n

\nThe CHMP positive opinion is a scientific recommendation to the European Commission (EC) to grant marketing authorization in Europe and will be reviewed by the EC, which has the authority to authorize medicines in the 27 Member States of the European Union, as well as Norway, Iceland and Liechtenstein. The final European Commission decision is expected later this year.\n<\/p>\n

\n\u201cTreatment options are extremely limited for people living with HIV whose virus is no longer effectively controlled by their current regimen. We are encouraged by this CHMP positive opinion for lenacapavir, as it is an important step toward a potential new treatment option for individuals with multi-drug resistant HIV,\u201d said Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences. \u201cWe look forward to the final decision by the European Commission and the potential for lenacapavir to help fill a critical unmet need for persons living with HIV with complex prior treatment histories.\u201d\n<\/p>\n

\nThe positive opinion is supported by data from the Phase 2\/3 CAPELLA trial, a double-blinded, placebo-controlled global multicenter study designed to evaluate the antiviral activity of lenacapavir administered every six months as a subcutaneous injection, in combination with other antiretroviral(s), in heavily treatment-experienced people with multi-drug resistant HIV-1 infection. In this patient population of high unmet medical need, 81% (n=29\/36) of participants receiving lenacapavir in addition to an optimized background regimen achieved an undetectable viral load (<50 copies\/mL) at Week 26. Additionally, CAPELLA participants achieved a mean increase in CD4 count of 81 cells\/\u00b5L. The New England Journal of Medicine published the primary outcome results of the CAPELLA trial in its May 11, 2022 issue – Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection<\/i><\/a>. Through Week 26, lenacapavir was generally well tolerated, with no serious adverse events related to lenacapavir as determined by the study investigator. The most common adverse events observed in the trial were injection-site reactions.\n<\/p>\n

\nLenacapavir is an investigational compound and is not approved by any regulatory authority for any use and its safety and efficacy are not established. There is no cure for HIV or AIDS.\n<\/p>\n

\nAbout Lenacapavir<\/b>\n<\/p>\n

\nLenacapavir is Gilead\u2019s potential first-in-class, investigational long-acting HIV-1 capsid inhibitor in development for the treatment of HIV-1 infection. The safety, efficacy and dosing of Gilead\u2019s investigational, long-acting HIV-1 capsid inhibitor lenacapavir are being evaluated in multiple ongoing clinical studies. Lenacapavir’s multi-stage mechanism of action is distinguishable from currently approved classes of antiviral agents and is designed to provide a new avenue for the development of long-acting therapy options for people with or at risk for HIV-1. While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV-1 at multiple stages of its lifecycle and has no known cross resistance to other existing drug classes. If authorized, lenacapavir would be the only HIV-1 treatment option administered twice yearly.\n<\/p>\n

\nAbout CAPELLA (NCT04150068)<\/b>\n<\/p>\n

\nCAPELLA is a Phase 2\/3, double-blinded, placebo-controlled global multicenter study designed to evaluate the antiviral activity of lenacapavir administered every six months as a subcutaneous injection in heavily treatment-experienced people with multi-drug resistant HIV-1 infection. CAPELLA includes men and women with HIV-1 and is being conducted at research centers in North America, Europe and Asia.\n<\/p>\n

\nIn CAPELLA, 36 participants with multi-class HIV-1 drug resistance and a detectable viral load while on a failing regimen were randomly allocated to receive oral lenacapavir or placebo in a 2:1 ratio for 14 days, in addition to continuing their failing regimen (functional monotherapy). An additional 36 participants were enrolled in a separate treatment cohort. Both cohorts are part of the ongoing maintenance period of the study evaluating the safety and efficacy of subcutaneous lenacapavir administered every six months in combination with an optimized background regimen. The primary endpoint was the proportion of participants randomly allocated to receive lenacapavir or placebo for 14 days, in addition to continuing their failing regimen, achieving \u22650.5 log10 copies\/mL reduction from baseline in HIV-1 RNA at the end of the functional monotherapy period.\n<\/p>\n

\nFollowing the 14-day functional monotherapy period, participants randomly allocated to receive lenacapavir or placebo, in addition to continuing their failing regimen, started open-label lenacapavir and an optimized background regimen, while those enrolled in a separate treatment cohort received open-label lenacapavir and an optimized background regimen on Day 1. This ongoing maintenance period of the study is evaluating the additional trial endpoints of safety and efficacy of subcutaneous lenacapavir administered every six months in combination with an optimized background regimen.\n<\/p>\n

\nFor further information, please see https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04150068<\/a>.\n<\/p>\n

\nAbout Gilead Sciences<\/b>\n<\/p>\n

\nGilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer.\n<\/p>\n

\nFor 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Gilead researchers have developed 11 HIV medications<\/a>, including the first single-tablet regimen to treat HIV and the first antiretroviral for pre-exposure prophylaxis (PrEP) to reduce the risk of acquiring HIV infection. These advances in medical research<\/a> have helped to transform HIV into a preventable, chronic condition for millions of people.\n<\/p>\n

\nGilead is committed to continued scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world. Through partnerships<\/a> and collaborations, the company also aims to improve education, expand access<\/a> and address barriers to care, with the goal of ending the HIV epidemic for everyone, everywhere. Gilead was recognized<\/a> as the number one philanthropic funder of HIV-related programs in a report released by Funders Concerned About AIDS.\n<\/p>\n

\nGilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead\u2019s ability to initiate, progress and complete clinical trials involving lenacapavir in the anticipated timelines or at all; the possibility of unfavorable results from ongoing and additional clinical trials involving lenacapavir; uncertainties relating to regulatory applications and related filing and approval timelines, including the risk that the EC may not grant marketing authorization for lenacapavir for the treatment of HIV-1 infection in a timely manner or at all; the risk that any regulatory approvals, if granted, may be subject to significant limitations on use; the possibility that Gilead may make a strategic decision to discontinue development of lenacapavir and as a result, lenacapavir may never be successfully commercialized; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and factors are described in detail in Gilead\u2019s Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.\n<\/p>\n

\nGILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. All other trademarks are the property of their respective owners.<\/i>\n<\/p>\n

\nFor more information about Gilead, please visit the company\u2019s website at <\/i>www.gilead.com<\/a>, follow Gilead on Twitter (<\/i>@Gilead Sciences<\/i><\/a>) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nJacquie Ross, Investors
\n
jacquie.ross@gilead.com<\/a><\/p>\n

Brian Plummer, Media
\n
brian.plummer@gilead.com<\/a><\/p>\n

Sarah Swift, Media (Europe)
\n
sarah.swift@gilead.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2013 Recommendation is Based on Week 26 Data from the CAPELLA Trial Showing Twice-Yearly Lenacapavir Achieved High Rates of Virologic Suppression in Heavily Treatment-Experienced People with HIV \u2013 \u2013 If Authorized, Lenacapavir Could Offer a New, Every Six-Month Treatment Option for People with Limited Treatment Choices \u2013 FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45476","6":"format-standard","7":"category-industry"},"yoast_head":"\nInvestigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u2013 Recommendation is Based on Week 26 Data from the CAPELLA Trial Showing Twice-Yearly Lenacapavir Achieved High Rates of Virologic Suppression in Heavily Treatment-Experienced People with HIV \u2013 \u2013 If Authorized, Lenacapavir Could Offer a New, Every Six-Month Treatment Option for People with Limited Treatment Choices \u2013 FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-24T12:01:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220623005107\/en\/778437\/21\/GCP_Primarylarge_%281%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV\",\"datePublished\":\"2022-06-24T12:01:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\\\/\"},\"wordCount\":1419,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220623005107\\\/en\\\/778437\\\/21\\\/GCP_Primarylarge_%281%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\\\/\",\"name\":\"Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220623005107\\\/en\\\/778437\\\/21\\\/GCP_Primarylarge_%281%29.jpg\",\"datePublished\":\"2022-06-24T12:01:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220623005107\\\/en\\\/778437\\\/21\\\/GCP_Primarylarge_%281%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220623005107\\\/en\\\/778437\\\/21\\\/GCP_Primarylarge_%281%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\/","og_locale":"en_US","og_type":"article","og_title":"Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV - Pharma Trend","og_description":"\u2013 Recommendation is Based on Week 26 Data from the CAPELLA Trial Showing Twice-Yearly Lenacapavir Achieved High Rates of Virologic Suppression in Heavily Treatment-Experienced People with HIV \u2013 \u2013 If Authorized, Lenacapavir Could Offer a New, Every Six-Month Treatment Option for People with Limited Treatment Choices \u2013 FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-24T12:01:58+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220623005107\/en\/778437\/21\/GCP_Primarylarge_%281%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV","datePublished":"2022-06-24T12:01:58+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\/"},"wordCount":1419,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220623005107\/en\/778437\/21\/GCP_Primarylarge_%281%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\/","url":"https:\/\/pharma-trend.com\/en\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\/","name":"Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220623005107\/en\/778437\/21\/GCP_Primarylarge_%281%29.jpg","datePublished":"2022-06-24T12:01:58+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220623005107\/en\/778437\/21\/GCP_Primarylarge_%281%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220623005107\/en\/778437\/21\/GCP_Primarylarge_%281%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/investigational-lenacapavir-receives-positive-chmp-opinion-for-people-with-multi-drug-resistant-hiv\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Investigational Lenacapavir Receives Positive CHMP Opinion for People With Multi-Drug Resistant HIV"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45476"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45476\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}